Glial fibrillary acidic protein in tumours of the nervous system

Delpech, Bertrand; Delpech, A; Vidard, M N; Girard, Nicole; Tayot, J; Clement, Jd.; Creissard, P

doi:10.1038/bjc.1978.5

Cited by 57 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In adult rat, the protein was found at the nodes of Ranvier of central and peripheral myelinated fibers and around some cerebral and cerebellar neurons (10), a finding consistent with the localization of hyaluronectin in oligodendroglial cells in primary dissociated cultures of newborn rat brain (11). Moreover, the antibodies also stained nonneural tissues, including the interstitial tissues ofrat renal medulla and of human mammary gland (12). Compared to the limited amount of hyaluronectin-immunoreactive material in adult rat tissues, large amounts were found with the polyclonal antibodies in the rat embryo, both in mesenchyma and brain (13).…”

mentioning

confidence: 60%

See 1 more Smart Citation

Brain-specific hyaluronate-binding protein: an immunohistological study with monoclonal antibodies of human and bovine central nervous system.

Bignami¹,

Dahl²

1986

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Hyaluronectin is a protein isolated from acid extracts of human brain by affinity chromatography on immobilized hyaluronate. With polyclonal antibodies, it was immunohistologically localized in the rat at the nodes of Ranvier of central and peripheral myelinated fibers and in mesenchymal tissues. Compared to adult rat, hyaluronectinimmunoreactive material was more abundant in embryonal rat brain and mesenchyma. We report a different localization in human and bovine tissues with monoclonal antibodies reacting with human hyaluronectin by NaDodSO4/PAGE and immunoblotting but not staining rat tissues by immunohistology. In human and calf the antigen reacting with hyaluronectin monoclonal antibodies was brain specific, while several peripheral tissues were stained by the polyclonal antibodies. In human and bovine central nervous system monoclonal antibodies stained white matter and tissues formed predominantly by glial fibers (e.g., subependymal glia). In white matter hyaluronectin-immunoreactive material formed a delicate mesh surrounding individual myelinated fibers, a pattern compatible with the distribution of fine astroglial processes in this location. Gray matter did not stain with monoclonal antibodies, the granular layer of the cerebellum excepted. The findings suggest that human hyaluronectin is heterogeneous and comprises at least two fractions. The main fraction is a brain-speciflic protein, probably produced by white matter astrocytes. Another fraction cross-reacting with rat is more abundant in embryonal tissues, including mesenchyma and brain.

show abstract

mentioning

confidence: 60%

“…Hyaluronectin was isolated from human brain as reported (9,15). Samples of cerebral hemispheres were obtained within [4][5][6][7][8][9][10][11][12][13][14][15][16][17][18][19][20] NaDodSO4/PAGE was run as reported (18) in 8% gels with 0.1% NaDodSO4. Samples were reduced with dithiothreitol.…”

Section: Methodsmentioning

confidence: 99%

Brain-specific hyaluronate-binding protein: an immunohistological study with monoclonal antibodies of human and bovine central nervous system.

Bignami¹,

Dahl²

1986

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

show abstract

“…Two early studies already address one of the most important questions considering GFAP in astrocytoma; is the GFAP protein in astrocytoma different from GFAP in the healthy brain, in respect of its immunochemical characteristics and expression level? Delpech et al () used radial immunodiffusion analysis to demonstrate that GFAP in healthy human brain extracts is immunochemically similar to GFAP in astrocytoma extracts (Delpech et al, ). This agrees with the study of Dittmann et al () who show, by rocket immunoelectrophoresis, that there are no immunochemical differences between GFAP isolated from astrocytoma and the adult human brain.…”

Section: Resultsmentioning

confidence: 99%

“…In 1971, upon the isolation of filaments from fibrous astrocytes, the 50 kDa type III intermediate filament glial fibrillary acidic protein (GFAP) was identified and characterized. One year later, high expression of GFAP in glioma with astrocyte characteristics, astrocytoma, was described for the first time, followed by many reports thereafter (Delpech et al, 1978;Uyeda, Eng, & Bignami, 1972;van der Meulen, Houthoff, & Ebels, 1978). Multiple studies characterized GFAP expression in glioma subtypes leading to the establishment † These authors share senior authorship.…”

mentioning

confidence: 98%

Importance of GFAP isoform‐specific analyses in astrocytoma

Bodegraven

Asperen

Robe

et al. 2019

Glia

View full text Add to dashboard Cite

Gliomas are a heterogenous group of malignant primary brain tumors that arise from glia cells or their progenitors and rely on accurate diagnosis for prognosis and treatment strategies. Although recent developments in the molecular biology of glioma have improved diagnosis, classical histological methods and biomarkers are still being used. The glial fibrillary acidic protein (GFAP) is a classical marker of astrocytoma, both in clinical and experimental settings. GFAP is used to determine glial differentiation, which is associated with a less malignant tumor. However, since GFAP is not only expressed by mature astrocytes but also by radial glia during development and neural stem cells in the adult brain, we hypothesized that GFAP expression in astrocytoma might not be a direct indication of glial differentiation and a less malignant phenotype. Therefore, we here review all existing literature from 1972 up to 2018 on GFAP expression in astrocytoma patient material to revisit GFAP as a marker of lower grade, more differentiated astrocytoma. We conclude that GFAP is heterogeneously expressed in astrocytoma, which most likely masks a consistent correlation of GFAP expression to astrocytoma malignancy grade. The GFAP positive cell population contains cells with differences in morphology, function, and differentiation state showing that GFAP is not merely a marker of less malignant and more differentiated astrocytoma. We suggest that discriminating between the GFAP isoforms GFAPδ and GFAPα will improve the accuracy of assessing the differentiation state of astrocytoma in clinical and experimental settings and will benefit glioma classification.

show abstract

“…It is a protein found normally in glial cells. Examples of neoplasms that stain positive for GFAP include: astrocytoma, glioblastoma, oligodendroglioma, schwannoma, and neurofibroma 19–21 . The Schwann cells of nonmyelinating peripheral nerves (autonomic nerves) also stain positive for GFAP and this phenomenon proved useful in identifying the Schwann cell origin of spindle cell tumor of blue eyed dogs 2 .…”

Section: Discussionmentioning

confidence: 99%

Anterior uveal spindle cell tumor in a cat

Evans

Lynch

Dubielzig

2010

Veterinary Ophthalmology

View full text Add to dashboard Cite

Based on its histopathologic characteristics, this iris tumor was diagnosed as a Schwann cell variant of a peripheral nerve sheath tumor (PNST) closely resembling the spindle cell tumor of blue-eyed dogs. Anterior uveal PNST has not been previously reported in cats to the authors' knowledge. The presence of Antoni type A and type B tissue patterns along with immunohistochemical staining may facilitate a diagnosis of PNST and rule out malignant melanoma.

show abstract

Glial fibrillary acidic protein in tumours of the nervous system

Cited by 57 publications

References 12 publications

Brain-specific hyaluronate-binding protein: an immunohistological study with monoclonal antibodies of human and bovine central nervous system.

Brain-specific hyaluronate-binding protein: an immunohistological study with monoclonal antibodies of human and bovine central nervous system.

Importance of GFAP isoform‐specific analyses in astrocytoma

Anterior uveal spindle cell tumor in a cat

Contact Info

Product

Resources

About